Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoGen Inc, Medical Devices Deals, 2012 to YTD 2018 10
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 12
ImmunoGen Enters into Research Agreement with Merck 13
Ventana Medical Systems Enters into Co-Development Agreement with ImmunoGen 14
CytomX Therapeutics Enters Into Co-Development Agreement With ImmunoGen fOR Probody-Drug Conjugates Therapies 15
Licensing Agreements 17
Takeda Enters into Licensing Agreement with ImmunoGen 17
CytomX Therapeutics Exercises Option for Licensing Agreement with ImmunoGen 18
ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 19
Equity Offering 20
ImmunoGen Raises USD150.7 Million in Public Offering of Shares 20
ImmunoGen Raises USD108.4 Million in Public Offering of Shares 22
ImmunoGen Plans to Raise up to USD50 Million in Public Offering 24
ImmunoGen Completes Public Offering Of Common Stock For US$100 Million 25
Debt Offering 27
ImmunoGen Raises USD100 Million in Private Placement of 4.5% Notes Due 2021 27
Asset Transactions 28
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 28
TPG Special Situations Partner to Acquire Kadcyla Royalty Rights from ImmunoGen for USD200 Million 29
ImmunoGen Inc – Key Competitors 30
ImmunoGen Inc – Key Employees 31
ImmunoGen Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Nov 02, 2018: ImmunoGen reports recent progress and third quarter 2018 operating results 33
Jul 27, 2018: ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results 35
May 04, 2018: ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results 37
Feb 09, 2018: ImmunoGen Reports Pipeline Progress and 2017 Operating Results 39
Nov 03, 2017: ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results 41
Jul 28, 2017: ImmunoGen Reports Recent Progress and Second Quarter 2017 Operating Results 43
May 05, 2017: ImmunoGen Reports Recent Progress and First Quarter 2017 Operating Results 45
Feb 17, 2017: ImmunoGen Reports Recent Progress and Operating Results for Six-Month Period and Quarter Ended December 31, 2016 47
Corporate Communications 49
Apr 25, 2018: ImmunoGen Appoints Blaine McKee as Executive Vice President and Chief Business Officer 49
Jan 23, 2017: ImmunoGen Announces Departure of Sandra Poole 50
Product News 51
03/14/2018: ImmunoGen Announces Presentations at AACR Annual Meeting Highlighting Continued Innovation in ADCs 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52
ImmunoGen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoGen Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoGen Inc, Medical Devices Deals, 2012 to YTD 2018 10
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 12
ImmunoGen Enters into Research Agreement with Merck 13
Ventana Medical Systems Enters into Co-Development Agreement with ImmunoGen 14
CytomX Therapeutics Enters Into Co-Development Agreement With ImmunoGen fOR Probody-Drug Conjugates Therapies 15
Takeda Enters into Licensing Agreement with ImmunoGen 17
CytomX Therapeutics Exercises Option for Licensing Agreement with ImmunoGen 18
ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 19
ImmunoGen Raises USD150.7 Million in Public Offering of Shares 20
ImmunoGen Raises USD108.4 Million in Public Offering of Shares 22
ImmunoGen Plans to Raise up to USD50 Million in Public Offering 24
ImmunoGen Completes Public Offering Of Common Stock For US$100 Million 25
ImmunoGen Raises USD100 Million in Private Placement of 4.5% Notes Due 2021 27
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 28
TPG Special Situations Partner to Acquire Kadcyla Royalty Rights from ImmunoGen for USD200 Million 29
ImmunoGen Inc, Key Competitors 30
ImmunoGen Inc, Key Employees 31
ImmunoGen Inc, Subsidiaries 32
List of Figures
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoGen Inc, Medical Devices Deals, 2012 to YTD 2018 10